News

The FDA has approved 2 abbreviated new drug applications (ANDAs) for everolimus (Afinitor) tablets for the treatment of patients numerous malignancies.

CAR T-cell therapy is an emerging targeted therapy that has large potential for patients whose disease is relapsed or refractory.

The combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) elicited a 100% overall response rate (ORR) in patients with relapsed indolent non-Hodgkin lymphoma (NHL) that was refractory to rituximab (Rituxan), according to findings of a single-arm, phase I/II trial presented at the 2019 ASH Annual Meeting.

Steroid use while cytokine release syndrome (CRS) and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurologic events.

Resistance to aromatase inhibitors (AIs) is a growing concern in patients with advanced hormone receptor (HR)–positive, HER2-negative breast cancer, said Hope S. Rugo, MD, FASCO, who added that although fulvestrant (Faslodex) has shown some activity in patients who develop ESR1 mutations, more effective treatment options are needed.

While cytoreductive nephrectomy has been a mainstay in kidney cancer treatment, there are factors to consider before using the procedure on patients with the disease.

Glioblastoma is historically difficult to treat, but recent research shows some potential for immunotherapy/vaccine combinations for these patients.

Recent findings showed patients with advanced melanoma had a favorable complete response to nivolumab and ipilimumab due to potential biomarkers in the disease.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to abatacept (Orencia) to prevent moderate or severe acute graft-versus-host disease (GvHD) in patients who underwent a hematopoietic stem cell transplant and are not related to their donors, according to Bristol-Myers Squibb, the manufacturer of the drug.

New findings show that while nurses need to provide more palliative care to patients, they are not prepared to do so, leading to high levels of moral distress.

The FDA has granted a priority review designation to pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)–unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.

The FDA has granted a priority review designation to a supplemental Biologics License Application (sBLA) for durvalumab (Imfinzi) for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).1

Here are the top 5 Oncology Nursing News® stories for November 2019.

JAK inhibitors have been the standard of care for patients with myelofibrosis, but now patients need novel agents to help.

The FDA has granted a priority review to the agent pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

New approvals in the treatment of patients with myeloma has led to the question of what sequencing of drugs will work best for patients.

Two new single agents led to brain penetrance and 2-hydroxyglutarate (2-HG) suppression in patients with low-grade glioma who harbor IDH1 mutations, according to updated findings.

New real-world data shows that PARP inhibitors have the potential to help patients with ovarian cancer and could be an affordable option for them.

Canada’s first immunotherapy oncology program provides patient education to not only help them understand the therapy but also mitigate immune-related adverse events.

Drug prices for cancer care are rising considerably, but biosimilars are poised to help patients with cancer handle these prices. Particularly, patients with breast cancer.

In this month’s episode of the "CURE Talks Cancer Podcast: Nursing Edition," we had the chance to talk with Betty Ferrell, FAACN, FCPN, MA, PhD, director of the Division of Nursing Research and Education at City of Hope, and discuss the important differences between palliative care and end of life care.

The FDA has approved acalabrutinib for the treatment of adult patients with CLL or SLL.

In a phase III trial of nivolumab/ipilimumab to treat patients with melanoma in the adjuvant setting results showed the drugs missed their coprimary end point.

New studies are showing the dawn of a new era in how cancer care teams will go about treating patients with small cell lung cancer with immunotherapy combinations.

The FDA accepts the application of a biosimilar of bevacizumab in the treatment of patients with NSCLC.

Immunotherapy as a frontline treatment for patients with advanced nonsquamous NSCLC is showing potential, but there is still additional testing that needs to be done.

Biosimilars are beginning to change the way oncology professionals treat patients with cancer, and this could help alleviate the financial burden of care.

Patients with cancer undergoing stem cell transplant are experiencing depression at higher rates than other cancer survivors, and special interventions are required to address their psychosocial needs.